Sarepta Therapeutics (SRPT) Operating Expenses (2010 - 2026)

Sarepta Therapeutics has reported Operating Expenses for 17 years, with the latest figure at $372.4 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 64.37% year-over-year to $372.4 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 billion (down 5.34% YoY), and the FY2025 full-year result was $2.9 billion, up 72.1% from the prior year.
• Operating Expenses for Q1 2026 stood at $372.4 million, down from $854.5 million in the prior quarter.
• The five-year high for Operating Expenses was $1.0 billion in Q1 2025, with the low at $297.7 million in Q1 2022.
• Average Operating Expenses over 5 years is $466.7 million, with a median of $391.6 million recorded in 2023.
• Year-over-year, Operating Expenses soared 176.11% in 2025 and tumbled 64.37% in 2026.
• Tracing SRPT's Operating Expenses over 5 years: stood at $365.3 million in 2022, then climbed by 1.89% to $372.2 million in 2023, then jumped by 33.47% to $496.7 million in 2024, then soared by 72.03% to $854.5 million in 2025, then tumbled by 56.42% to $372.4 million in 2026.
• The last three Operating Expenses figures came in at $372.4 million (Q1 2026), $854.5 million (Q4 2025), and $502.7 million (Q3 2025), per Business Quant data.

Peer Comparison